Canada Markets closed
LATEST UPDATE

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

We are taking a short break, but we will be back next week. Stay tuned!

Evofem Biosciences, Inc. (EVFM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6930-0.0238 (-3.32%)
At close: 4:00PM EDT
0.6991 +0.01 (+0.88%)
After hours: 07:53PM EDT
Sign in to post a message.
  • R
    Richard
    I respect everyone who posts on this board because I own and perhaps you own shares of
    Evfm common stock and so we have a mutual interest. Management must quickly
    change their strategy in order to increase quarterly sales to three or four hundred thousand units.
    The retail price must be reduced and Evfm must sell direct to the consumer in order to succeed.
  • C
    Chi-Town
    Morgan Stanley Downgrades Evofem Biosciences to Underweight Rating From Equal-Weight, Lowers PT to $0.80 From $1
    BY MT Newswires
    — 9:48 AM ET 10/14/2021
    09:48 AM EDT, 10/14/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
    Price: 0.74, Change: -0.01, Percent Change: -1.99
    MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
  • A
    Andy
    Saundra must have typed up this PR herself.

    “Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share.”

    $1000.00 per share. 😂
  • C
    Chi-Town
    Largest borrow rate increases among liquid names (TheFlyOnTheWall)
    BY The Fly
    — 8:45 AM ET 10/11/2021
    Latest data shows the largest indicative borrow rate increases among liquid option names include: (IRNT) 721.97% +232.36, REE Automotive ( REE ) 16.23% +0.71, AEye Inc ( LIDR
    Loading...
    Loading...
    ) 95.10% +0.63, (DNA) 129.02% +0.57, Sirius XM (SIRI) 0.96% +0.34, Iron Source (IS) 0.60% +0.31, Root Inc ( ROOT
    Loading...
    Loading...
    ) 1.61% +0.25, Bsquare Corp ( BSQR ) 20.41% +0.25, Skillz ( SKLZ
    Loading...
    Loading...
    ) 2.49% +0.17, and Evofem Biosciences ( EVFM ) 31.04% +0.17.
  • j
    j
    Bottom line, the product itself is respectable so take that concern off the table. Sales will continue to increase. If it’s not a blockbuster, it will still have a nice market share no matter what. That’s beyond debate as far as I’m concerned. It’s settled in my mind.

    The concern is how does this company stay afloat for the next 12 months without enough cash. Sales will help. Share price would help. (And CEO and top executive pay cut would help, reputation-wise.)
  • R
    Richard
    Upon conversion of the EVFM preferred stock to EVFM common stock, the convertor will own 16,666,667
    shares of common stock at a cost of $10,000,000. Thus, the convertor will acquire the common stock at
    $0.60 per share and the outstanding shares of EVFM will be increased by 16,666,667 shares. This is not
    good news to me. How about you? Greetings from weakyzeky.
  • C
    Chi-Town
    Yesterday presentation at LD Micro....I was quite interesting:

    https://www.youtube.com/watch?v=Obu_GyQxP0w
    Evofem Biosciences ( EVFM ) presentation at LD Micro VIRTUAL
    www.youtube.com
  • hd
    OMG WE ARE MOONING
  • A
    AQ
    going to $1 by earnings announcement after growing sales numbers every week for last couple of weeks
  • c
    chuck
    We have just learned from Bloomberg that sales increased last week by 30%
    after increasing 67% the week before that.
    Week of Sept 10. 1,173
    Week of Sept 17. 1,961
    Week of Sept 24. 2,543
    These are the total prescriptions each week for the last 3 weeks only.
    PHEXXI is beginning to sell.
  • c
    comery
    If you are interested in seeing some really solid transformation to your trading bottom line then you need to check out (http://trademarketview.tech).
  • T
    Timmy
    If you lost a ton on this stock

    Load up on CALA you will make it all back this year

    CALA Q4 play with catalysts ahead;

    ✅2 significant data catalysts coming up in Q4 (which started yesterday);

    ✅$80M cash / no debt / low cash burn

    (Analysts are on CALA for Keapsake data giving >100% upside potential on interim study results Q4) $25B market for NSCLC

    (Also new Phase 1b interim data to be presented at North American Cystic Fibrosis conference Nov 2-5) $8B market for CB

    ✅Licensed their CD73 with Antengene earlier this year - Calithera will receive an upfront payment and potential development, regulatory and sales milestones of up to $255.0 million.

    CRVS ran 277% earlier this month after AstraZeneca CD73 Success, as it’s the only baby bio with CD73 that isn’t partnered...

    ✅Consolidation on chart for 6 months now, with significant catalysts ahead $2.50 break needed for a bigger move

    ✅Per 8-k in September 2021; they reached a Settlement agreement with Incyte - who will pay CALA for missing 2 milestone payments after a licensing deal signed in 2017

    ✅Good Tutes like BVF, Primecap Management, and Adage all hold.

    ✅(BVF disclosed ownership of 7,452,331 shares in July an increase of 70% from their February 2021 filing to become 10% owner / major shareholder)

    BVF was the main institution behind the FPRX turnaround last year which went from $4s ~> $38 in a $1.9B Buyout by Amgen after a bidding war

    $STSA $ASMB $BVXV $IFRX
  • J
    J
    Any shareholder here should sign this as well as share it;

    https://www.contraceptivecoverage.com/sign-the-petition
    Sign The Petition | CHFCC
    contraceptivecoverage.com
  • C
    Chi-Town
    BRIEF-Evofem Biosciences Announces $10 Million Registered Direct Offering Of Series B Preferred Stock
    BY Reuters
    — 6:34 AM ET 10/12/2021
    Oct 12 (Reuters) - Evofem Biosciences Inc ( EVFM
    Loading...
    Loading...
    ):

    * EVOFEM BIOSCIENCES ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING OF SERIES B PREFERRED STOCK

    * EVOFEM BIOSCIENCES INC ( EVFM ) - PROVIDES RUNWAY INTO Q1 2022 Source text for Eikon: Further company coverage:
  • F
    Ferris Bueller
    New here. Should continue to see growth based on last two weeks of great sales numbers. Over a million views on Annie’s Instagram. I would think mostly from like type women.
  • M
    M
    where are the phexxi ads running? I'm seeing them on CNBC which seems targeted more at investors than consumers. It's a well designed ad - but are they placing it in places where it will drive prescription growth?
  • c
    chuck
    Bloomberg Phexxi sales results showing impressive gains this week.
  • a
    alan
    All my posts on this board have been flagged and removed. Kind of childish especially since none of the comments on this board have ANY effect on the overall stock price or influence any but a few investors to buy or sell.
  • D
    Dan
    I’m buying 100k tomorrow
  • a
    alan
    This is shaping up for not only an upturn, but consolidating for a potential run. The charts are looking good, and the Bollinger looks like we are set up for a "squeeze" some time next week. (chart haters "gonna hate" but the proof will be in results). The celebrity media campaign will not only generate sales, but, more importantly, will get EVFM exposure to potential new investors.